Two patients receive the same cancer diagnosis, start the same standard treatment, and experience completely different results. One responds well within weeks. The other sees little improvement and develops significant side effects. The diagnosis was identical; the underlying biology was not. Genomics is one of the tools helping medicine understand exactly why that happens, and increasingly, what to do about it.
What Is the Genetic Code?
DNA is the molecule that carries the instructions for building and operating the human body, organized into structures called chromosomes. Genes are specific segments of DNA that code for proteins, the molecules responsible for most biological functions. A genetic variant is a difference in DNA sequence between individuals, and while most variants have no meaningful effect, some influence traits, disease risk, or how a person responds to a particular medication.
Genetics and Genomics Are Not Exactly the Same
Genetics traditionally refers to the study of individual genes and how specific traits or conditions are inherited. Genomics takes a broader view, studying an organism’s entire genome, including how genes interact with each other and with environmental factors. This distinction matters because many common diseases are not caused by a single gene but by complex interactions across many genes and other influences, which genomics is better equipped to study.
How Genomic Information Gets From DNA to Healthcare
Turning genetic information into a clinical decision follows a fairly consistent pathway. A biological sample, typically blood or saliva, is collected and sequenced or tested for specific variants. Identified variants are then interpreted against known databases linking specific genetic changes to disease risk or drug response. That interpretation is placed in clinical context, considering family history and other risk factors, before ultimately informing a medical decision, whether that involves prevention, diagnosis, or treatment selection.
Where Genomics Is Already Changing Medicine
Rare Disease Diagnosis
Genomic sequencing has dramatically shortened the diagnostic journey for many rare genetic conditions, some of which previously took years and dozens of specialist visits to identify.
Cancer Genomics
Tumor genomic profiling identifies specific mutations driving a particular cancer, allowing oncologists to select targeted therapies designed to act on those exact mutations rather than relying solely on broad chemotherapy approaches.
Pharmacogenomics
Certain genetic variants affect how quickly a person metabolizes specific medications, information that can guide dosing decisions for drugs where the wrong dose carries meaningful risk.
Reproductive and Prenatal Applications
Genetic carrier screening and prenatal genetic testing help prospective parents understand inherited disease risk before or during pregnancy, informing family planning decisions.
Risk Assessment
Genetic testing for certain hereditary conditions, such as specific inherited cancer syndromes, can identify individuals at significantly elevated risk, allowing for earlier or more frequent screening.
Infectious Disease Surveillance
Genomic sequencing of pathogens allows public health researchers to track how infectious diseases spread and mutate, informing outbreak response and vaccine development.
Precision Medicine: Matching Treatment to Biology
Precision medicine uses genomic and other biological information to tailor treatment more closely to an individual’s specific biology, rather than applying a single standard approach to everyone with the same diagnosis. Genomic information is one important input into this process, but it works alongside other factors including a patient’s overall health, other medical conditions, and personal treatment preferences, rather than serving as the sole determinant of treatment.
What Genetic Testing Can and Cannot Tell You
A positive genetic test result indicates that a specific variant was identified but does not necessarily mean a person will develop the associated condition, since many genetic risk factors influence probability rather than certainty. A negative result reduces likelihood but does not eliminate all risk, since not every possible contributing variant may have been tested.
Variants of uncertain significance are changes in DNA whose effect on health is not yet well understood, an increasingly common finding as sequencing technology identifies more variation than current medical knowledge can fully interpret. It is also important to distinguish risk variants, which increase probability, from deterministic findings that essentially guarantee a condition will develop, since the two carry very different implications for a patient. Incidental findings, unrelated to the original reason for testing, occasionally arise and require careful discussion about whether and how to disclose them.
Genomics in Everyday Clinical Practice
Beyond specialized applications like cancer treatment and rare disease diagnosis, genomic information is gradually becoming a more routine part of general clinical care. Some primary care practices now incorporate pharmacogenomic testing to guide medication choices for common conditions such as depression or high cholesterol, where genetic variation can meaningfully affect how a patient responds to a first-choice medication.
Family history remains one of the simplest and most accessible forms of genetic risk assessment, often serving as the initial signal that prompts a referral for more formal genetic testing. A detailed family history discussion, covering conditions across multiple generations, continues to play an important complementary role even as direct genomic testing becomes more widely available and affordable.
The Ethical Questions Behind Genomic Medicine
Genomic information raises distinct ethical considerations beyond typical medical privacy concerns. A genetic result reveals information not just about the individual tested but potentially about their biological relatives as well, raising questions about family disclosure and consent. Long-term data storage and the potential for future re-analysis as scientific understanding improves add further complexity.
Depending on jurisdiction, legal protections against insurance or employment discrimination based on genetic information vary considerably, making it important for patients to understand applicable protections in their own location before testing. Equity concerns also persist, since genomic databases have historically underrepresented certain populations, potentially limiting the accuracy of risk predictions for those groups.
Direct-to-Consumer Genetic Testing
Consumer genetic testing kits, purchased online or in stores without a clinician’s involvement, have made genomic information accessible to a much broader audience than clinical testing alone. These tests can provide interesting information about ancestry and certain traits, and some now include limited health-related risk reporting. It is important to understand that consumer tests typically screen for a narrow set of well-studied variants, meaning a negative result does not rule out broader genetic risk that a more comprehensive clinical test might detect.
Results from consumer genetic tests that suggest an elevated health risk generally warrant confirmation through clinical-grade testing and discussion with a genetic counselor or physician before any medical decisions are made based on them.
What Comes Next for Genomics
Sequencing technology continues to become faster and less expensive, expanding access to genomic testing across more clinical settings. Multiomics approaches, combining genomic data with other biological layers such as protein and metabolic profiles, promise a more complete picture of individual biology than genomics alone can provide. AI-assisted interpretation is helping researchers make sense of the enormous volume of genomic data now being generated, though this remains an evolving area requiring careful validation.
Population-level genomic research and continued advances in gene editing techniques represent active areas of scientific investigation, though it is important to distinguish these research frontiers from treatments currently available in standard clinical practice.
Genomics is expanding the information available to clinicians in ways that were not possible a generation ago, from earlier diagnosis of rare conditions to more targeted cancer treatment. That expanded information also brings new questions around interpretation, privacy, and equitable access that the field continues to work through as the technology matures.
This article provides general educational information about genomics and does not constitute medical advice. Anyone considering genetic testing should discuss the decision with a qualified healthcare provider or genetic counselor.
FAQ
Q: What is genomics in healthcare?
A: Genomics in healthcare refers to using information about a person’s complete genetic makeup to inform diagnosis, treatment selection, and disease risk assessment. It plays an increasingly important role in cancer care, rare disease diagnosis, and medication management.
Q: What is the difference between genetics and genomics?
A: Genetics traditionally studies individual genes and inheritance patterns, while genomics studies the entire genome and how genes interact with each other and the environment. Genomics offers a broader view suited to complex, multi-gene conditions.
Q: Can genetic testing predict disease?
A: Genetic testing can identify variants associated with increased risk for certain conditions, but most results indicate probability rather than certainty. Many diseases result from a combination of genetic and environmental factors rather than genetics alone.
Q: What is precision medicine?
A: Precision medicine tailors treatment decisions to an individual’s specific biology, including genomic information, rather than applying the same approach to everyone with a given diagnosis. It is used most extensively today in cancer treatment.
Q: How is genomics used in cancer treatment?
A: Tumor genomic profiling identifies specific mutations driving a cancer, which can guide selection of targeted therapies designed to act on those exact mutations. This approach has become standard for several cancer types.
Q: What is pharmacogenomics?
A: Pharmacogenomics studies how genetic variants affect an individual’s response to specific medications, including how quickly a drug is metabolized. This information can help guide dosing decisions for certain high-risk medications.
Q: Are genetic test results always accurate?
A: Genetic testing is generally highly accurate at detecting the presence of a specific variant, but interpreting what that variant means for health can be less certain, particularly for variants of uncertain significance. Results should be interpreted with guidance from a genetic counselor or physician.